Navigation Links
ESBATech Announces Successful Completion of Phase I Clinical Study for Lead Antibody Fragment in Ophthalmic Indications
Date:9/8/2008

Preclinical Pharmacokinetic Data to be Presented at the 7th International

Symposium on Uveitis in Germany

ZURICH, Switzerland, Sept. 8 /PRNewswire/ -- ESBATech AG, a leading developer of antibody fragment therapeutics, today announced that the company has successfully completed its Phase I clinical study of the company's lead product candidate, ESBA105, in ophthalmic indications. In April 2008, ESBATech initiated the Phase I study designed to evaluate the safety, tolerability and pharmacokinetic profile of ESBA105, when delivered topically via eye drops in healthy volunteers. This trial was conducted as a single and repeated dose escalation study in Switzerland. ESBA105 is a single-chain antibody fragment directed against TNF-alpha, and it is being developed initially for ophthalmic indications. Several additional clinical studies are in the preparation stages.

Manfred Zierhut, Professor in the Department of Ophthalmology at the University of Tuebingen in Germany, will present preclinical pharmacokinetic data on ESBA105 on Friday, September 12, 2008, at the 7th International Symposium on Uveitis in Constance, Germany. For more information on the symposium and on Prof. Zierhut's abstract, please visit http://www.iusg2008.org/.

Dominik Escher, Ph.D., Chief Executive Officer of ESBATech AG, commented, "The completion of this Phase I study with ESBA105 in ophthalmic indications marks a critical clinical milestone for the company. Recently, ESBATech secured CHF 23M (USD 22M) in an extended Series B venture financing round. This financing will fund further clinical studies with ESBA105 in ophthalmic indications, as well as build broad franchises in ophthalmology, rheumatology and respiratory diseases for ESBA105 and other antibody fragments. We look forward to announcing the results of this Phase I study and future clinical trials."

Peter Lichtlen, M.D., Ph.D., Hea
'/>"/>

SOURCE ESBATech AG
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. ESBATechs Antibody Fragments Demonstrate Penetration into the Eye with Topical Delivery via Eye Drops
2. Immureboost Inc Announces a Change of Name to Fountain Healthy Aging Inc
3. Ondine Announces Presentation of Positive Clinical Trial Results at the American Academy of Periodontologys 94th Annual Meeting
4. MedQuist Announces Additions to Board of Directors
5. Zimmer Holdings, Inc. Announces Agreement to Acquire Abbott Spine, an Innovator in Spinal Technology
6. Martek Announces Third Quarter 2008 Financial Results
7. ABMAC Foundation Announces Publication of an Historic Volume Documenting the Creation of a National Health Care System in Taiwan
8. China Bio Energy Holdings Group Announces Participation in the Susquehanna Second Annual Beijing Management Summit
9. American Oriental Bioengineering Announces Participation in September Investor Conferences
10. Human Genome Sciences Announces Process Development and Manufacturing Alliance With Hospira
11. Mindray Medical International Announces Second Quarter 2008 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... 2015 WuXi PharmaTech (Cayman) Inc. (NYSE: ... and technology platform company serving the global pharmaceutical, ... an Investigational New Drug (IND) application for WuXi ... has been accepted for review by the China ... In September 2012, MedImmune, the global biologics research ...
(Date:3/26/2015)... March 26, 2015 PRC Clinical, a ... today several management and executive appointments effective immediately. , ... Officer (CFO) and member of the Board of Directors. ... Operations, and Sue Dowden will assume the position of ... current Chief Operations Officer (COO), has been appointed to ...
(Date:3/26/2015)... Massachusetts and CINCINNATI ... Shire plc (LSE: SHP, NASDAQ: SHPG ) ... a three-year, broad research collaboration for rare diseases. The ... develop novel therapies to treat rare diseases with ... commercialization capabilities with Cincinnati Children,s research expertise. As ...
(Date:3/26/2015)... (PRWEB) March 26, 2015 "In America," the ... the United States that is hosted by legendary film actor ... topic of botany in an upcoming segment. , Botany ... in reality it is actually quite a bit more complicated ... of different types of living organisms, from the smallest bacteria ...
Breaking Biology Technology:Investigational New Drug Application for WuXi MedImmune's Monoclonal Antibody Accepted for Review by CFDA 2Investigational New Drug Application for WuXi MedImmune's Monoclonal Antibody Accepted for Review by CFDA 3PRC Clinical Announces Key Management Appointments and Launches East Coast Operations 2PRC Clinical Announces Key Management Appointments and Launches East Coast Operations 3Shire and Cincinnati Children's Establish Rare Disease Research Collaboration 2Shire and Cincinnati Children's Establish Rare Disease Research Collaboration 3Shire and Cincinnati Children's Establish Rare Disease Research Collaboration 4Shire and Cincinnati Children's Establish Rare Disease Research Collaboration 5
... Mass., Nov. 9, 2010 Boston Scientific Corporation (NYSE: ... of its Vercise™ Deep Brain Stimulation (DBS) System as ... multi-center, prospective trial designed to examine the improvement of ... the Vercise DBS System for the treatment of Parkinson,s ...
... novel, real-time imaging system, scientists have tracked a group ... lungs, into the body and out again, providing a ... particles which could be used in developing therapeutic agents ... greater understanding of the health effects of air pollution. ...
... (Nasdaq: KNDL ), a leading, global full-service ... the third quarter of 2010 of $131.4 million. Contract ... to $10.4 million or 1.3 percent of the Company,s ... book-to-bill of 1.5. New business authorizations (backlog) at Sept. ...
Cached Biology Technology:Boston Scientific Begins Patient Enrollment in Clinical Trial Assessing Deep Brain Stimulation for Parkinson's Disease 2Boston Scientific Begins Patient Enrollment in Clinical Trial Assessing Deep Brain Stimulation for Parkinson's Disease 3Boston Scientific Begins Patient Enrollment in Clinical Trial Assessing Deep Brain Stimulation for Parkinson's Disease 4Scientist chronicle nanoparticles' journey from the lungs into the body 2Scientist chronicle nanoparticles' journey from the lungs into the body 3Kendle Announces Third Quarter 2010 Results 2Kendle Announces Third Quarter 2010 Results 3Kendle Announces Third Quarter 2010 Results 4Kendle Announces Third Quarter 2010 Results 5Kendle Announces Third Quarter 2010 Results 6
(Date:3/5/2015)... 5, 2015 In Brazil , ... already using these solutions and 42 percent planning to invest ... approximately 25 percent of the companies will be investing in ... majority of companies in the region are currently opting for ... model will command significant attention in the coming years. This ...
(Date:3/2/2015)... March 2, 2015 Synaptics Inc. (NASDAQ: ... human interface solutions, today announced a new implementation ... to enable rapid and secure transactions and reliable ... gaming is a turnkey solution providing mouse and ... quickly integrate fingerprint ID solutions into their product ...
(Date:2/25/2015)... , Feb. 25, 2015  ABC Financial Services ... in the Health and Fitness Industry, today announced ... to MYiCLUBonline.  The latest upgrade includes advances to ... of cardless check-in via Identity One fingerprint biometrics. ... time through interactive displays at the International Health, ...
Breaking Biology News(10 mins):Two of Every Three Brazilian Companies will have Invested in Cloud by 2015, Finds Frost & Sullivan 2Two of Every Three Brazilian Companies will have Invested in Cloud by 2015, Finds Frost & Sullivan 3Two of Every Three Brazilian Companies will have Invested in Cloud by 2015, Finds Frost & Sullivan 4Synaptics Unveils New Fingerprint ID Solution for Gamers 2Synaptics Unveils New Fingerprint ID Solution for Gamers 3ABC Financial Unveils New Software Enhancements 2ABC Financial Unveils New Software Enhancements 3
... 2011 Based on its recent analysis of ... recognizes Cardiocom with the 2011 North American Frost ... integrated clinical telehealth services that offer significant cost ...   http://photos.prnewswire.com/prnh/20081117/FSLOGO ) Cardiocom combines advanced ...
... Inexpensive igloo-shaped, pollution-eating devices nicknamed "Poo-Gloos" can ... treatment facilities for towns outgrowing their waste-treatment lagoons, ... results of this study show that it is ... hundreds of thousands, if not millions of dollars, ...
... rethinking what happens on the surface of things, engineers ... biofilm colonies exhibit an unmatched ability to repel ... across yet only hundreds of microns thick, such slimy ... pipes to teeth and are notoriously resistant to antimicrobial ...
Cached Biology News:Frost & Sullivan Recognizes Cardiocom as a Technology Enabler for Superior Cost-Effective Remote Chronic Care Management 2Frost & Sullivan Recognizes Cardiocom as a Technology Enabler for Superior Cost-Effective Remote Chronic Care Management 3Frost & Sullivan Recognizes Cardiocom as a Technology Enabler for Superior Cost-Effective Remote Chronic Care Management 4Igloo-shaped 'Poo-Gloos' eat sewage 2Igloo-shaped 'Poo-Gloos' eat sewage 3Igloo-shaped 'Poo-Gloos' eat sewage 4Igloo-shaped 'Poo-Gloos' eat sewage 5A pesky bacterial slime reveals its survival secrets 2A pesky bacterial slime reveals its survival secrets 3
Lysozyme C (W-20)...
... ventilated and BR4i refrigerated multifunction centrifuges are equally ... at a low sound level with a large ... Their AUTO-LOCK rotor exchange system without tools ensures ... within seconds. Instant rotor exchange (5 ...
... X-Gal (5-bromo-4-chloro-3-indoyl-beta-D-galactopyranoside) is a ... identify recombinant plasmids. In ... and IPTG, lac ... blue, whereas recombinant colonies ...
... an enhanced form of Tobacco Etch Virus ... active, and significantly more stable than native ... Protease specifically recognizes a seven amino acid ... it useful for removing affinity tags from ...
Biology Products: